NCT05380986

Camrelizumab Combined With Apatinib Mesylate

A Real World Study of Camrelizumab Combined With Apatinib Mesylate in Solid Tumors

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors

Detailed description

According to current studies, the combination of camrelizide and apatinib mesylate has significant efficacy and controllable toxicity in the treatment of solid tumors. This study adopted camrelizumab combined with apatinib mesylate in the treatment of solid tumors, aiming to further explore the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors and provide more research data for the treatment of solid tumors.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	Camrelizumab combined with apatinib mesylate	Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Timeline

• Start date: 2022-05-20
• Primary completion: 2024-05-01
• Completion: 2025-05-01
• First posted: 2022-05-19
• Last updated: 2022-05-19

Locations

1 site across 1 country: China